A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 458-462

  Kollmannsberger, C ^a   Quietzsch, D ^b   Haag, C ^c   Lingenfelser, T ^d   Schroeder, M ^e   Hartmann, J T ^a   Baronius, W ^b   Hempel, V ^b   Clemens, M ^f   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e ST JOHANNES HOSPITAL   (Germany)

^f Krankenanstalt der Boromaeerinnen ^*  (Germany)

Author keywords

Chemotherapy; Continuous infusion; Gastric cancer; Metastatic; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0033931245     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1295     Document Type: Article

References (39)

1. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274
2. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L et al (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma [see comments]. J Clin Oncol 9: 625-630
3. Belani C, Luketich JD, Landreaneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keean RJ, Posner M, Seeger J, Lembersky B (1997) Efficacy of cisplatin, 5-flurouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol 24: 89-92
4. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L (1997a) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8: 396-399
5. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, Kanz L (1997b) Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 24: S19-S19
6. Cascinu S, Ficarelli R, Safi MA, Graziano F, Catalano G, Cellerino R (1997) A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 33: 1699-1702
7. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9: 307-310
8. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, Chi CW (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14-18
9. Findley M, Cunningham D (1993) Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 19: 29-44
10. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168
11. Harstrick A, Vanhoefer U, Wilke H et al (1994) Interaction of taxol with cisplatin, eloposide and 5-EU in human gastric carcinoma cell lines. Proc Am Assoc Cancer Res 35: 332
12. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Meyer F, Kanz L, Bokemeyer C (1999) Milomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti-Cancer Drugs 10: 729-733
13. Ilson DH, Ajani JA, Bhalla K, Forastiere AA, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluororuacil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834
14. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI (1996) Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710
15. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. Am J Stat Assoc 53: 457-481
16. Kelsen DP, Atiq OT, Saltz L et al (1992) FAMTX versus etoposide, doxorubiein, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548
17. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818
18. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85: 295-301
19. Klein HO, Wickramanayak PD, Farrkh GR et al (1986) 5-fluroruracil (5-FU), adriamycin (ADM) and methotrexate (MTX) - a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol 84: 86
20. Miller AB, Hoodgstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-211
21. Murad AM (1999) Chemotherapy for advanced gastric cancer: Focus on new agents and combinations. Cancer Control 6: 361-368
22. Okada Y, Anai H, Hattori T, Maehara Y, Nishimura J, Sugimachi K, Nawata H (1991) Cisplatin plus continous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. Anticancer Drugs 2: 453-456
23. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H (1989) Phase II study with etoposide, doxorubicin, and cisplatin in advanced and measurable gastric cancer. J Clin Oncol 9: 1310-1317
24. Pyrhönen S, Kuitunen Z, Nyandoto P et al (1995) Randomized comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591
25. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser Ph, Yehou M, Elias D, Cvitkovic E, Armand JP, Droz J-P (1994) Efficacy of combined 5-fluroruracil and cisplatin in advanced gastre carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263-1269
26. Rowinsky EK, Cazenave LA, Donchower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259
27. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-florouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925
28. Schabel FM, Trader ML, Laster WR, Corbett TH, Griswold DP (1979) Cisdichlorodiammine-platinum (II): combination chemotherapy and cross resistance studies with tumor of mice. Cancer Treat Rep 63: 1459-1473
29. Schipper DL, Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7: 137-149
30. Vanhoefer U, Wilke H, Weh J, Clemens M, Harstrick A, Stahl M, Hossfeld DK, Seeber S (1994) Weekly high-dose 5-FU and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5: 850-851
31. Vanhoeler U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S (1995) Schedule-dependent antagonism of pachtaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97
32. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Jofe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hicksth T (1999) Long-term survival later epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80: 269-272
33. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JH, Hughes M, Mansi J, Findley M, Hill A, Oates J, Nicolson M, Hicksih T, O'Brian M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-167
34. Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober C, Link H, Meyer HJ, Lucke B et al (1990) High-dose folinic acid/etoposide/5-fluroruracil in advanced gastric cancer - a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8: 65-70
35. Wilke H, Wils J, Rougier P et al (1995) Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/5-FU in advanced gastric cancer (GC). Atrial of the EORTC Gatrointeslinal Tract Cooperative Group and the AIO (Arbettsgemeinschaft Internistische Onkologie). Proc Am Soc Clin Oncol 14: 206
36. Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, Kohne C, Klassen U, Harstrick A, Schmoll HJ, Seeber S (1996a) Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 6: 123-126
37. Wilke H, Korn M, Köhne C, Fink U, Preusser P, Vanhoefer U, Wiegmann T, Stahl M, Harstrick A, Klassen U, Schmoll HJ, Seeber S (1996b) Phase II results of weekly infusional high-dose FU (HD-FU) plus folinic caid (FA) and biweekly cisplatin (C) in advanced gastric cancer. Ann Oncol 7(suppl 5): 46
38. Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23: 397-406
39. World Health Organization (1998) World Health Report 1998: A vision for all. World Health Organization, Geneva, Switzerlan